|
業務類別
|
Biotechnology |
|
業務概覽
|
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor (MCR) system. Its product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. It is also developing, dependent on resources for development activities, MC1R agonist products, with potential to treat inflammatory and autoimmune diseases, such as dry eye disease, which is also known as keratoconjunctivitis sicca, uveitis, diabetic retinopathy, and inflammatory bowel disease. It has one operating segment life science. |
| 公司地址
| 301 Carnegie Center Drive, Suite 304, Princeton, NJ, USA, 08540 |
| 電話號碼
| +1 609 495-2200 |
| 傳真號碼
| +1 609 495-2202 |
| 公司網頁
| https://www.palatin.com |
| 員工數量
| 25 |
| Mr. Stephen Thomas Wills, C.P.A. |
Chief Financial Officer, Principal Accounting Officer, Chief Operating Officer, Executive Vice President, Secretary and Treasurer |
美元 670.00K |
28/09/2026 |
| Dr. Carl Spana,PhD |
Chief Executive Officer, President and Director |
美元 721.00K |
28/09/2026 |
|
|
| Ms. Arlene M. Morris |
Independent Director |
28/09/2026 |
| Dr. Alan W. Dunton,M.D. |
Independent Director |
28/09/2026 |
| Dr. Carl Spana,PhD |
Chief Executive Officer, President and Director |
28/09/2026 |
| Dr. John K.A. Prendergast,PhD |
Non-Executive Chairman of the Board |
28/09/2026 |
|
|
|
|